CHMP2B突变携带者症状前阶段脑脊液神经丝轻链浓度升高
该横断面探索性研究分析丹麦FTD-3家系16例突变携带者和14例非携带者的脑脊液生物标志物,发现突变携带者脑脊液NfL浓度显著升高,且症状前携带者高于非携带者、症状性携带者高于症状前携带者;t-tau、p-tau和YKL-40无差异,Aβ38和Aβ40显著降低。提示NfL可能有助于检测FTD-3突变携带者神经退行性变的起始。
要点
- CHMP2B突变携带者脑脊液NfL浓度显著高于非携带者。
- 症状前携带者NfL已升高,症状性携带者进一步升高。
- t-tau、p-tau和YKL-40在携带者与非携带者间无差异。
核心结论
- 症状前FTD-3突变携带者脑脊液NfL已升高,提示从症状前到症状期存在持续的神经退行性变过程。
- 脑脊液NfL虽非FTD-3病理特异,但可能作为检测FTD-3突变携带者神经退行性变起始的有价值生物标志物。
研究设计与样本
- 横断面探索性研究,分析丹麦FTD-3家系16例突变携带者和14例非携带者的脑脊液样本。
- 检测指标包括t-tau、NfL、p-tau、Aβ38、Aβ40、Aβ42和YKL-40。
主要发现
- 脑脊液NfL浓度在突变携带者中显著高于非携带者。
- 脑脊液NfL浓度在症状性突变携带者中显著高于症状前携带者,在症状前携带者中显著高于非携带者。
- t-tau、p-tau和YKL-40浓度在对照组与突变携带者间无差异。
- 脑脊液Aβ38和Aβ40浓度在突变携带者中显著低于非携带者,Aβ42无显著差异。
临床怎么用
- 对于CHMP2B突变携带者,脑脊液NfL或可用于监测神经退行性变的起始。
- 脑脊液NfL升高不具FTD-3病理特异性,需结合遗传背景解读。
局限性
- 横断面设计无法确定NfL随时间变化的轨迹。
- 样本量较小(16例携带者、14例非携带者),结果需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: A rare cause of familial frontotemporal dementia (FTD) is a mutation in the CHMP2B gene on chromosome 3 (FTD-3), described in a Danish family. Here we examine whether CSF biomarkers change in the preclinical phase of the disease. METHODS: In this cross-sectional explorative study, we analyzed CSF samples from 16 mutation carriers and 14 noncarriers from the Danish FTD-3 family. CSF biomarkers included total tau (t-tau) and neurofilament light chain (NfL) as a marker for neurodegeneration, phosphorylated tau (p-tau) as a marker for tau pathology, β-amyloid (Aβ) 38, 40, and 42 (Aβ38, Aβ40, and Aβ42) to monitor Aβ metabolism, and YKL-40 as a marker of neuroinflammation. Aβ isoform concentrations were measured using a multiplexed immunoassay; t-tau, p-tau, NfL, and YKL-40 concentrations were measured using sandwich ELISAs. RESULTS: CSF NfL concentration was significantly increased in mutation carriers vs noncarriers. Further, CSF NfL concentration was significantly higher in symptomatic mutation carriers compared to presymptomatic carriers, and also significantly higher in presymptomatic carriers compared to noncarriers. No differences in t-tau and p-tau and YKL-40 concentrations between controls and mutation carriers were observed. CSF concentrations of the Aβ peptides Aβ38 and Aβ40 but not Aβ42 were significantly lower in mutation carriers compared to noncarriers. CONCLUSIONS: Increased NfL levels in presymptomatic individuals and in symptomatic patients with FTD-3 indicate a continuous process of neurodegeneration from the presymptomatic to symptomatic state. Although not specific for FTD-3 pathology, our data suggest that CSF NfL could serve as a valuable biomarker to detect onset of neurodegeneration in FTD-3 mutation carriers.
引用
- Rostgaard N, Roos P, Portelius E, et al. CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers. Neurology. 2017. PMID: 29237796. doi:10.1212/WNL.0000000000004799
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。